AMT-191
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease
Trial Timeline
Jun 5, 2024 → Apr 30, 2031
NCT ID
NCT06270316About AMT-191
AMT-191 is a phase 1/2 stage product being developed by uniQure for Fabry Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06270316. Target conditions include Fabry Disease.
What happened to similar drugs?
9 of 20 similar drugs in Fabry Disease were approved
Approved (9) Terminated (4) Active (10)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06270316 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 38 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 35 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 44 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 27 |
| agalsidase beta | Sanofi | Approved | 35 |
| Tropicamide | Sanofi | Pre-clinical | 26 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 35 |
| agalsidase beta | Sanofi | Approved | 43 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 43 |
| Gabapentin + placebo | Sanofi | Phase 2 | 27 |
| Agalsidase beta | Sanofi | Approved | 43 |
| GZ/SAR402671 | Sanofi | Phase 2 | 35 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 35 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 3 | 40 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 44 |
| Iohexol | Sanofi | Phase 1 | 21 |
| GZ/SAR402671 | Sanofi | Phase 2 | 35 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 35 |
| Agalsidase beta | Sanofi | Approved | 43 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 43 |